Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 11/20 | 0.41 |
| ▸ | EP300 | Q09472 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26944532 | 0.94 | EPHX2 (0.50) | EPHX2GBA1EP300 | |
| SCHEMBL16234065 | 0.90 | CSNK2A1 (0.40) | EPHX2GBA1HRH4HRH3GGPS1 | |
| SCHEMBL23221642 | 0.88 | EPHX2 (0.50) | EPHX2GBA1HRH4HRH3 | |
| SCHEMBL17776274 | 0.87 | EPHX2 (0.46) | EPHX2GBA1HRH4HRH3 | |
| SCHEMBL23974562 | 0.86 | EPHX2 (0.43) | EPHX2GBA1EP300HRH4HRH3 | |
| SCHEMBL17776313 | 0.84 | EPHX2 (0.52) | EPHX2GBA1EP300 | |
| SCHEMBL24469396 | 0.83 | EPHX2 (0.41) | EPHX2GBA1EP300HRH4HRH3 | |
| SCHEMBL23974561 | 0.83 | GGPS1 (0.43) | EPHX2HRH4HRH3GGPS1FDPS | |
| SCHEMBL16903657 | 0.83 | GGPS1 (0.44) | EPHX2GBA1HRH4HRH3GGPS1 | |
| SCHEMBL18768800 | 0.83 | EPHX2 (0.57) | EPHX2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |